These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24928062)

  • 1. Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events.
    Rockman S; Dyson A; Koernig S; Becher D; Ng M; Morelli AB; Barnden M; Tang ML; Pearse M; Maraskovsky E
    Vaccine; 2014 Jun; 32(30):3861-8. PubMed ID: 24928062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine.
    Rockman S; Becher D; Dyson A; Koernig S; Morelli AB; Barnden M; Camuglia S; Soupourmas P; Pearse M; Maraskovsky E
    Vaccine; 2014 Jun; 32(30):3869-76. PubMed ID: 24681272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine.
    Maraskovsky E; Rockman S; Dyson A; Koernig S; Becher D; Morelli AB; Barnden M; Camuglia S; Bodle J; Vandenberg K; Wang IM; Cristescu R; Loboda A; Citron M; Fontenot J; Hung D; Schoofs P; Pearse M
    Vaccine; 2012 Dec; 30(51):7400-6. PubMed ID: 23063831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The manufacturing process should remain the focus for severe febrile reactions in children administered an Australian inactivated influenza vaccine during 2010.
    Li-Kim-Moy J; Booy R
    Influenza Other Respir Viruses; 2016 Jan; 10(1):9-13. PubMed ID: 26258888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Aug; 59(31):989-92. PubMed ID: 20703207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
    Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
    Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms.
    Blyth CC; Currie AJ; Wiertsema SP; Conway N; Kirkham LA; Fuery A; Mascaro F; Geelhoed GC; Richmond PC
    Vaccine; 2011 Jul; 29(32):5107-13. PubMed ID: 21640152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events associated with 2010 CSL and other inactivated influenza vaccines.
    Kelly HA; Skowronski DM; De Serres G; Effler PV
    Med J Aust; 2011 Sep; 195(6):318-20. PubMed ID: 21929484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events.
    Dey A; Gidding HF; Menzies R; McIntyre P
    Vaccine; 2014 Apr; 32(19):2204-8. PubMed ID: 24613527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
    Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study.
    Stowe J; Andrews N; Bryan P; Seabroke S; Miller E
    Vaccine; 2011 Nov; 29(51):9467-72. PubMed ID: 22019757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
    AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.